We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
Mater Board has seven sub-committees that meet regularly throughout the year to guide direction across key strategic areas of Mater's business. The sub-committees make recommendations for action to the Mater Misericordiae Limited Board, which retains collective responsibility for decision making.
Professor Maher Gandhi is the Chief Executive Officer and Director of Clinical Research at Mater Research and a pre-eminent senior staff haematologist.
As the Director of Clinical Research, Professor Maher’s role is to set strategy and create a clinical research program that influences future national and international health policy and practice through the full integration of Mater Research with clinical care. Whilst centred on Mater Research, the role also has close involvement with Mater Health, Mater Education and Mater Foundation.
Professor Gandhi joins Mater from the Diamantina Institute, The University of Queensland and as a Pre-Eminent Senior Staff Haematologist and Head of Academic Haematology at the Princess Alexandra Hospital. A Specialist Haematologist for 16 years, Maher’s medical speciality training was completed in the UK in Cambridge and Newcastle-Upon-Tyne, and in Toronto Canada. He completed a PhD in Viral Immunology in Cambridge, came to Brisbane on a Fellowship in 2003, and has stayed in Brisbane supported by uninterrupted NHMRC funding since 2005.
His past appointments include Chair of the Australasian Leukaemia Lymphoma Group Scientific Sub-Committee and Chair of the Metro South HREC. Professor Gandhi’s research interests relate to the tumour microenvironment in lymphoma. He is passionate about promoting translational research and personalised medicine, implementing interdisciplinary research, innovative clinical trials, and forging stronger links between Scientists and Clinicians.